{"id":13734,"date":"2018-01-05T11:38:24","date_gmt":"2018-01-05T11:38:24","guid":{"rendered":"https:\/\/celonpharma.com\/?p=13734"},"modified":"2022-10-18T14:52:50","modified_gmt":"2022-10-18T14:52:50","slug":"noteszhd","status":"publish","type":"post","link":"https:\/\/celonpharma.com\/en\/noteszhd\/","title":{"rendered":"NoteSzHD"},"content":{"rendered":"
\"\"<\/div>\n

 <\/p>\n

NoteSzHD \u2013 “New therapy in psychotic disorders and Huntington’s disease with special focus on cognitive deficits” .<\/strong><\/h2>\n

\u2013 the project received co-financing from the National Centre for Research and Development in the amount of PLN 26,730,836 under THE PROGRAMME OF SCIENTIFIC RESEARCH AND DEVELOPMENT entitled STRATEGMED \u201cPROPHYLAXYS AND TREATMENT OF DISEASES OF AFFLUENCE\u201d<\/p>\n

The project is being implemented by Celon Pharma in collaboration with five scientific partners: the Nencki Institute of Experimental Biology in the Polish Academy of Sciences, the Mossakowski Medical Research Centre<\/p>\n

in the Polish Academy of Sciences, Institute of Pharmacology of the Polish Academy of Sciences, the Medical University of Lodz and the Poznan University of Medical Sciences. Celon Pharma is responsible for key activities associated with the development of the drug. The tasks of the remaining members of the consortium consist in exploration of mechanisms of action of phosphodiesterase 10A inhibitors (PDE10A).
\nCelon Pharma has conducted work on innovative PDE10A inhibitors since 2013. Additional support and interest from the scientific community is an opportunity to accelerate the pace of works on the drug to be used is psychotic disorders and Huntington’s disease and to make the therapy available to patients.<\/p>\n

Total cost of the STRATEGMED project:<\/strong>:PLN 40 279 820<\/p>\n","protected":false},"excerpt":{"rendered":"

  NoteSzHD \u2013 “New therapy in psychotic disorders and Huntington’s disease with special focus on cognitive deficits” .<\/p>\n","protected":false},"author":11,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[54],"tags":[],"class_list":["post-13734","post","type-post","status-publish","format-standard","hentry","category-pl-co-financed-projects-ended"],"acf":[],"yoast_head":"\nNoteSzHD - Celon Pharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/celonpharma.com\/en\/noteszhd\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NoteSzHD - Celon Pharma\" \/>\n<meta property=\"og:description\" content=\"  NoteSzHD \u2013 “New therapy in psychotic disorders and Huntington’s disease with special focus on cognitive deficits” .\" \/>\n<meta property=\"og:url\" content=\"https:\/\/celonpharma.com\/en\/noteszhd\/\" \/>\n<meta property=\"og:site_name\" content=\"Celon Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2018-01-05T11:38:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-10-18T14:52:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/celonpharma.com\/wp-content\/uploads\/2018\/01\/pasek-celonko-note.jpg\" \/>\n<meta name=\"author\" content=\"S\u0142awomir Ni\u017cnik\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"S\u0142awomir Ni\u017cnik\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/noteszhd\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/noteszhd\\\/\"},\"author\":{\"name\":\"S\u0142awomir Ni\u017cnik\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/44c54386ed112173d6e8bcbeb6425338\"},\"headline\":\"NoteSzHD\",\"datePublished\":\"2018-01-05T11:38:24+00:00\",\"dateModified\":\"2022-10-18T14:52:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/noteszhd\\\/\"},\"wordCount\":203,\"image\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/noteszhd\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/celonpharma.com\\\/wp-content\\\/uploads\\\/2018\\\/01\\\/pasek-celonko-note.jpg\",\"articleSection\":[\"PL - co-financed projects ended\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/noteszhd\\\/\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/noteszhd\\\/\",\"name\":\"NoteSzHD - Celon Pharma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/noteszhd\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/noteszhd\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/celonpharma.com\\\/wp-content\\\/uploads\\\/2018\\\/01\\\/pasek-celonko-note.jpg\",\"datePublished\":\"2018-01-05T11:38:24+00:00\",\"dateModified\":\"2022-10-18T14:52:50+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/44c54386ed112173d6e8bcbeb6425338\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/noteszhd\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/celonpharma.com\\\/en\\\/noteszhd\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/noteszhd\\\/#primaryimage\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/wp-content\\\/uploads\\\/2018\\\/01\\\/pasek-celonko-note.jpg\",\"contentUrl\":\"https:\\\/\\\/celonpharma.com\\\/wp-content\\\/uploads\\\/2018\\\/01\\\/pasek-celonko-note.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/noteszhd\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NoteSzHD\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/\",\"name\":\"Celon Pharma\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/44c54386ed112173d6e8bcbeb6425338\",\"name\":\"S\u0142awomir Ni\u017cnik\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NoteSzHD - Celon Pharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/celonpharma.com\/en\/noteszhd\/","og_locale":"en_US","og_type":"article","og_title":"NoteSzHD - Celon Pharma","og_description":"  NoteSzHD \u2013 “New therapy in psychotic disorders and Huntington’s disease with special focus on cognitive deficits” .","og_url":"https:\/\/celonpharma.com\/en\/noteszhd\/","og_site_name":"Celon Pharma","article_published_time":"2018-01-05T11:38:24+00:00","article_modified_time":"2022-10-18T14:52:50+00:00","og_image":[{"url":"https:\/\/celonpharma.com\/wp-content\/uploads\/2018\/01\/pasek-celonko-note.jpg","type":"","width":"","height":""}],"author":"S\u0142awomir Ni\u017cnik","twitter_card":"summary_large_image","twitter_misc":{"Written by":"S\u0142awomir Ni\u017cnik","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/celonpharma.com\/en\/noteszhd\/#article","isPartOf":{"@id":"https:\/\/celonpharma.com\/en\/noteszhd\/"},"author":{"name":"S\u0142awomir Ni\u017cnik","@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/44c54386ed112173d6e8bcbeb6425338"},"headline":"NoteSzHD","datePublished":"2018-01-05T11:38:24+00:00","dateModified":"2022-10-18T14:52:50+00:00","mainEntityOfPage":{"@id":"https:\/\/celonpharma.com\/en\/noteszhd\/"},"wordCount":203,"image":{"@id":"https:\/\/celonpharma.com\/en\/noteszhd\/#primaryimage"},"thumbnailUrl":"https:\/\/celonpharma.com\/wp-content\/uploads\/2018\/01\/pasek-celonko-note.jpg","articleSection":["PL - co-financed projects ended"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/celonpharma.com\/en\/noteszhd\/","url":"https:\/\/celonpharma.com\/en\/noteszhd\/","name":"NoteSzHD - Celon Pharma","isPartOf":{"@id":"https:\/\/celonpharma.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/celonpharma.com\/en\/noteszhd\/#primaryimage"},"image":{"@id":"https:\/\/celonpharma.com\/en\/noteszhd\/#primaryimage"},"thumbnailUrl":"https:\/\/celonpharma.com\/wp-content\/uploads\/2018\/01\/pasek-celonko-note.jpg","datePublished":"2018-01-05T11:38:24+00:00","dateModified":"2022-10-18T14:52:50+00:00","author":{"@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/44c54386ed112173d6e8bcbeb6425338"},"breadcrumb":{"@id":"https:\/\/celonpharma.com\/en\/noteszhd\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/celonpharma.com\/en\/noteszhd\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/celonpharma.com\/en\/noteszhd\/#primaryimage","url":"https:\/\/celonpharma.com\/wp-content\/uploads\/2018\/01\/pasek-celonko-note.jpg","contentUrl":"https:\/\/celonpharma.com\/wp-content\/uploads\/2018\/01\/pasek-celonko-note.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/celonpharma.com\/en\/noteszhd\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/celonpharma.com\/en\/"},{"@type":"ListItem","position":2,"name":"NoteSzHD"}]},{"@type":"WebSite","@id":"https:\/\/celonpharma.com\/en\/#website","url":"https:\/\/celonpharma.com\/en\/","name":"Celon Pharma","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/celonpharma.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/44c54386ed112173d6e8bcbeb6425338","name":"S\u0142awomir Ni\u017cnik"}]}},"_links":{"self":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/13734","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/comments?post=13734"}],"version-history":[{"count":2,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/13734\/revisions"}],"predecessor-version":[{"id":26354,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/13734\/revisions\/26354"}],"wp:attachment":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/media?parent=13734"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/categories?post=13734"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/tags?post=13734"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}